Key result
In patients with atrial fibrillation following bioprosthetic valve surgery or mitral repair, DOAC use was not significantly associated with an altered risk of stroke or systemic thromboembolism compared to VKA (VKA vs DOAC HR 0.831).
Why the study?
Does a direct oral anticoagulant (DOAC) reduce stroke or systemic thromboembolism compared to a vitamin K antagonist (VKA) in patients with atrial fibrillation discharged after surgical bioprosthetic valve replacement or mitral repair?
Does a direct oral anticoagulant (DOAC) reduce stroke or systemic thromboembolism compared to a vitamin K antagonist (VKA) in patients with atrial fibrillation discharged after surgical bioprosthetic valve replacement or mitral repair?
Hazard Ratio: 0.831 (95% CI 0.441–1.564)
p-value: p=0.143
This editorial highlights that DOACs may be a reasonable therapeutic option compared to VKAs for carefully selected patients with AF after surgical bioprosthetic valve replacement or mitral repair, bridging a gap between atrial fibrillation and valvular heart disease guidelines.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Chevli et al. (2026) conducted an editorial in Atrial fibrillation after bioprosthetic valve replacement or mitral repair (n=2,645). Direct oral anticoagulant (DOAC) vs. Vitamin K antagonist (VKA) was evaluated on Stroke or systemic thromboembolism (HR 0.831, 95% CI 0.441-1.564, p=0.143). In patients with atrial fibrillation following bioprosthetic valve surgery or mitral repair, DOAC use was not significantly associated with an altered risk of stroke or systemic thromboembolism compared to VKA (VKA vs DOAC HR 0.831).
Synapse has enriched 5 related papers. Consider them for comparative context: